These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33600068)

  • 81. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA
    Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
    AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients.
    Macías J; Téllez F; Rivero-Juárez A; Palacios R; Morano LE; Merino D; Collado A; García-Fraile L; Omar M; Pineda JA;
    J Viral Hepat; 2019 Jan; 26(1):48-54. PubMed ID: 30199593
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Characterization of CD4⁺ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients.
    Hodowanec AC; Brady KE; Gao W; Kincaid SL; Plants J; Bahk M; Landay AL; Huhn GD
    J Acquir Immune Defic Syndr; 2013 Nov; 64(3):232-40. PubMed ID: 24131865
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
    Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
    HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
    PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Characteristics of CD8
    Lu X; Song B; Weng W; Su B; Wu H; Cheung AKL; Zhang T; Gao Y
    Viral Immunol; 2023 Jan; 36(1):25-32. PubMed ID: 36346310
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8
    Vranjkovic A; Deonarine F; Kaka S; Angel JB; Cooper CL; Crawley AM
    Front Immunol; 2019; 10():1926. PubMed ID: 31456810
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
    Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
    J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: a prospective observational study.
    Angelidakis G; Pritchard H; Yibirin M; Jiang Y; Mustafayev K; Torres HA
    Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115719. PubMed ID: 35605562
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
    d'Arminio Monforte A; Tavelli A; Rossotti R; Gagliardini R; Saracino A; Lo Caputo S; Sala M; Quiros-Roldan E; Mussini C; Girardi E; Cozzi-Lepri A; Antinori A; Puoti M;
    Liver Int; 2023 Oct; 43(10):2130-2141. PubMed ID: 37649460
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons.
    Auma AWN; Shive CL; Lange A; Damjanovska S; Kowal C; Zebrowski E; Pandiyan P; Wilson B; Kalayjian RC; Canaday DH; Anthony DD
    Front Immunol; 2021; 12():641230. PubMed ID: 33912168
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration.
    HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
    Antivir Ther; 2012; 17(8):1541-50. PubMed ID: 22869294
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy.
    Farcomeni S; Moretti S; Fimiani C; Sulekova LF; Vescio F; Sernicola L; Maggiorella MT; Remoli AL; Picconi O; Mosca L; Esvan R; Biliotti E; Ciccozzi M; Sgarbanti M; Taliani G; Borsetti A
    Pathogens; 2021 Nov; 10(11):. PubMed ID: 34832642
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Decreased Activated CD4
    Skinner NE; Vergara C; El-Diwany R; Paul H; Skaist A; Wheelan SJ; Thomas DL; Ray SC; Balagopal A; Bailey JR
    Viral Immunol; 2021 Nov; 34(9):622-631. PubMed ID: 34672777
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of hepatitis C infection on HIV-induced apoptosis.
    Laskus T; Kibler KV; Chmielewski M; Wilkinson J; Adair D; Horban A; Stańczak G; Radkowski M
    PLoS One; 2013; 8(10):e75921. PubMed ID: 24098405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.